Comments
Shares of Aurobindo Pharma slipped on Q4 results. The company's net profit declined 0.65 per cent to Rs 528.8 crore in the quarter ended March, missing analyst estimates.
The drugmaker had posted a net profit of Rs 532.2 crore in the corresponding quarter in FY17.
Revenue from operations for the quarter under review rose 11.2 per cent to Rs 4,049.1 crore, compared with Rs 3,641.63 crore in the year-ago period. Earnings before interest, tax, depreciation, and amortisation (EBITDA) margin stood at 19.9 per cent.
The drugmaker stock plunged as much as 6.2 per cent to Rs 567.95, its lowest in a week. The stock posted its biggest intraday fall since November 10, 2017.
The stock was down 12.02 per cent this year as of Monday's close. Over 2.3 million shares changed hands vs 30-day average of 1.5 million shares.
(With inputs from Reuters)
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.